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Abstract: Measurement of inspiratory capacity (IC) as a marker of dynamic lung hyperinﬂ  ation 
has been shown to correlate with dyspnea and exercise performance in stable COPD, and is 
therefore of potential utility in the management of this condition. We have examined whether 
similar relationships exist during acute exacerbations of COPD and asthma in order to deter-
mine whether there is a role for IC monitoring in acute management of these conditions. Eight 
patients with COPD and ten with asthma requiring hospital admission for acute exacerbations 
were studied with spirometry (including IC) at admission and at discharge and had concurrent 
self-perceived resting dyspnea ratings recorded. Over the admission there were signiﬁ  cant 
improvements in resting dyspnea for the COPD group only, and improvements in spirometric 
indices in the asthma group only. No signiﬁ  cant correlations were found between changes in 
dyspnea and changes in IC, in terms of acute responses to bronchodilator and in response to 
treatment over the hospital admission. These data suggest that dynamic hyperinﬂ  ation during 
acute exacerbations of COPD and asthma is not as sensitive an indicator of resting dyspnea as 
in stable disease. A role for IC monitoring in the management of acute exacerbations of these 
diseases has not been identiﬁ  ed.
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Introduction
Demonstration of airﬂ  ow obstruction is an essential requirement in the diagnosis of 
chronic obstructive pulmonary disease (COPD). The forced expiratory volume in one 
second (FEV1) is the spirometric index most commonly used to detect the presence 
of COPD, to characterize its severity and to determine bronchodilator response (ATS 
1991). Although FEV1 is a strong prognostic indicator in COPD, it correlates poorly 
with both dyspnea level and limitation to exercise performance (O’Donnell et al 1999), 
arguably the symptoms which are of most relevance to patients.
As well as being deﬁ  ned by the presence of airﬂ  ow obstruction, COPD is character-
ized by dynamic hyperinﬂ  ation of the lungs. Recent studies suggest that improvements 
in spirometric indices of hyperinﬂ  ation in COPD are more closely related to dyspnea 
relief than are other more commonly-used measurements of airway caliber such as 
the FEV1 (O’Donnell et al 1998; O’Donnell et al 1999; Taube et al 2000; Boni et al 
2002). Traditionally, the more complex measurements of total lung capacity (TLC) 
and functional residual capacity (FRC) have been used to detect and quantify hyper-
inﬂ  ation. However, the inspiratory capacity (IC) provides an indirect measurement of 
end expiratory lung volume and is a technically simpler test.
Inspiratory capacity has been shown to increase signiﬁ  cantly in ‘irreversible’ COPD 
(Pellegrino et al 1998; Tantucci et al 1998; O’Donnell et al 2001), even in the absence 
of improvement in FEV1 (Tantucci et al 1998; O’Donnell et al 2001) indicating that International Journal of COPD 2007:2(4) 652
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functional improvement is possible, independent of changes 
in maximal ﬂ  ow. Furthermore, increases in IC following 
bronchodilator are signiﬁ  cantly correlated with improvements 
in dyspnea at rest (O’Donnell et al 1999; Taube et al 2000; 
Di Marco et al 2003), with dyspnea during exercise (O’Donnell 
et al 1998; O’Donnell et al 1999), and with exercise perfor-
mance (O’Donnell et al 1999; Diaz et al 2000). Monitoring 
IC has also been useful in describing changes in dynamic 
hyperinﬂ  ation in response to oxygen therapy in COPD (Alvisi 
et al 2003), and in response to induced bronchoconstriction in 
asthma (Lougheed et al 1993; Tantucci et al 1999).
These studies suggest that the measurement of IC could 
potentially be incorporated into the assessment and manage-
ment of COPD as a simple, objective and clinically relevant 
measurement of disease status. The majority of previous 
studies investigating the utility of IC measurements in COPD 
have been performed in stable disease. The question of the 
applicability and usefulness of IC measurements during acute 
exacerbations of COPD has received little attention. We 
wished to determine if there is a role for IC measurement in 
the clinical management of acute exacerbations of COPD. 
In addition, given the relationship between IC and dyspnea 
observed in induced bronchoconstriction in asthma (Lougheed 
et al 1993; Tantucci et al 1999), IC measurement may also 
have a role in the management of asthma exacerbations.
The aims of the present study were (1) to investigate the 
relationships between dyspnea and IC during acute exacerba-
tions of COPD and asthma, and (2) to assess the relationship 
between changes in IC and in dyspnea over the course of a 
hospital admission for an exacerbation of COPD or asthma.
Methods
Subjects
Adults requiring hospital admission for management of acute 
exacerbations of either asthma or COPD were prospectively 
recruited within 24 hours of admission. All subjects had 
received standard bronchodilator and corticosteroid therapy in 
the Accident and Emergency Department. Exclusion criteria 
were inability to reliably perform spirometry or to compre-
hend the use of the Borg dyspnea scale. The study protocol 
was approved by our institution’s medical research ethics 
committee and all subjects gave written informed consent.
Respiratory function tests
Respiratory function tests were performed using a 
computerized spirometry system (Sensormedics Vmax, 
Yorba Linda, USA) on two separate occasions: (1) within 
24 hours of admission and (2) immediately prior to discharge 
from hospital. At least 4 hours abstinence from short-acting 
beta-2 agonists and anticholinergic therapy was required prior 
to each set of tests. A minimum of one minute of quiet tidal 
breathing was allowed on the mouthpiece-ﬂ  owmeter assem-
bly prior to each of at least three measurements of inspiratory 
capacity (IC) and slow vital capacity (VC). Best VC and 
average of three IC measurements matching to within 10% 
were used for analysis. Following these measurements, maxi-
mal ﬂ  ow volume curves were performed in accordance with 
ATS recommendations (ATS 1995). All spirometric testing 
was repeated 10 minutes after supervised administration of 
200 μg of salbutamol delivered by metered dose inhaler via 
spacer. Resting dyspnea scores using the modiﬁ  ed Borg scale 
(Borg 1982) were obtained immediately prior to baseline and 
again immediately prior to post bronchodilator respiratory 
function testing. All baseline testing was performed within 
24 hours of admission, and all tests were repeated in an 
identical fashion at the time of hospital discharge.
Statistical analyses
Student’s t-test was used for statistical analysis of paired 
comparisons and linear correlation used to detect relation-
ships between variables. A p value of 0.05 was considered 
statistically signiﬁ  cant.
Results
Twelve subjects with asthma and nine with COPD were 
recruited for the study and performed baseline measurements, 
however complete data was obtained in ten subjects with 
asthma and in eight with COPD. Reasons for non-completion 
were, in all cases, unwillingness to repeat spirometric measure-
ments at the time of discharge. Only results from those subjects 
who completed the study are included in this report.
Subject characteristics are shown in Table 1. Subjects in 
the asthma group were younger and predominantly female. 
The COPD group was predominantly male and had a higher 
pack year history of cigarette smoking.
Acute changes after bronchodilator
Tables 2a and 2b show the respiratory function data at both 
visits to the laboratory (within 24 hours of admission and 
at the time of discharge) for the asthma and COPD groups 
respectively. There were statistically significant acute 
improvements in dyspnea following bronchodilator for both 
patient groups on both visits. In addition, there were small 
acute bronchodilator improvements in VC at admission 
and in IC at discharge in the asthmatic group. No other 
parameter achieved statistically signiﬁ  cant change following International Journal of COPD 2007:2(4) 653
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bronchodilator. Figure 1 shows spirometric and dyspnea 
values for individual patients.
Changes over the admission
Respiratory function data for both groups at discharge are 
shown in Tables 2a and 2b. Post-bronchodilator values were 
considered to provide more appropriate data for comparison 
over the course of the admission. The asthma group showed 
signiﬁ  cant improvements in all measures of respiratory func-
tion (p = 0.05 for FEV1, p = 0.05 for VC, p = 0.04 for FEV1/VC 
and p = 0.006 for IC), whereas the COPD group showed no 
statistically signiﬁ  cant changes. In contrast, resting dyspnea 
scores did not alter over the course of the admission in the 
asthma group, however there was a small improvement in 
resting dyspnea in the COPD group (p = 0.04).
Comparisons between asthma and COPD
Degree of airﬂ  ow obstruction as measured by the FEV1/VC 
ratio was more severe in the COPD group compared with the 
asthma group: 42% versus 63% at admission, 42% versus 
70% at discharge (p  0.0001 for both). Although there was 
no statistical difference between the admission FEV1 for 
the asthma and COPD groups, at discharge the FEV1 was 
signiﬁ  cantly higher in the asthma group (p = 0.016). Thus, 
notable differences were observed between the two patient 
groups in the changes in measured indices over the course of 
the admission. Spirometric indices improved in the asthma 
group, and dyspnea scores improved in the COPD group.
Correlations between parameters
Acute changes in lung function parameters and in dyspnea 
scores following inhaled bronchodilator are shown in Figure 2 
and reveal no signiﬁ  cant relationships in either patient group. 
Data obtained at time of discharge similarly showed no signiﬁ  -
cant correlation between these measurements. There was also 
no signiﬁ  cant correlation between changes in these measures 
over the course of the admission (Figure 3).
Discussion
We report an absence of correlation observed between 
change in dyspnea score and change in IC over the course 
of a hospital admission for treatment of exacerbations of 
asthma or COPD.
The theoretical reasoning that reductions in end expiratory 
lung volume should lead to improved lung mechanics and 
decreased work of breathing in COPD has been supported by 
a number of clinical studies over the past decade (O’Donnell 
et al 1998, 1999; Taube et al 2000; Boni et al 2002). These 
studies have demonstrated that measures of lung hyperinﬂ  a-
tion correlate more strongly with dyspnea at rest and during 
exercise and with exercise performance than does FEV1. 
This work suggests that the emphasis in monitoring disease 
status in COPD should be shifted away from measures of 
airway caliber and function to measures of the degree of lung 
hyperinﬂ  ation. Whilst functional residual capacity (FRC) 
and other lung volumes (such as residual volume and total 
lung capacity) have traditionally been used to describe lung 
hyperinﬂ  ation, their measurement requires sophisticated, 
expensive instrumentation which is not always readily acces-
sible. Relying on the assumption that total lung capacity does 
Table 2a Mean (SEM) respiratory function and dyspnea data for patients with asthma. Baseline to post bronchodilator (Post BD) 
t-test comparisons are indicated by the p-value in the table
 Admission      Discharge 
  Baseline  Post BD  p  Baseline  Post BD  p
FEV1 (L)  1.46 (0.21)  1.60 (0.22)  0.10  1.95 (0.27)  2.01 (0.28)  0.19
VC (L)  2.37 (0.26)  2.52 (0.28)  0.04  2.74 (0.31)  2.79 (0.30)  0.14
FEV1/VC (%)  61 (3.8)  63 (2.8)  0.51  70 (3.2)  70 (2.8)  0.67
IC (L)  2.03 (0.18)  2.15 (0.19)  0.08  2.26 (0.18)  2.36 (0.17)  0.02
Dyspnea (Borg)  3.9 (0.6)  2.6 (0.3)  0.02  2.6 (0.4)  2.0 (0.3)  0.005
Table 1 Admission characteristics for all subjects completing 
the study. Values quoted are means (range). Statistical difference 
between groups indicated by * (p  0.001) or # (p  0.0001)
 Asthma  COPD
Number of subjects  10  8
Male/Female 1/9  7/1
Age (years)*  43 (19–71)  71 (66–73)
BMI (kg/m2)  30 (20–39)  26 (21–33)
Smoking history  2 current, 3 ex, 5 never  3 current, 5 ex
Pack years #  3 (0–22)  64 (25–116)
Hospital admission (days)  3.3   3.4 
FEV1 (% pred.)  54 (37–89)  42 (23–60)
VC (% pred.)  74 (56–112)  79 (59–95)
FEV1/VC (%)*  61 (44–79)  40 (30–49)
IC (% pred.)  94 (73–124)  91 (55–117)
Dyspnea (Borg)  3.9 (0.5–7.0)  3.5 (1.0–5.0)International Journal of COPD 2007:2(4) 654
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not change, IC can be used to provide a surrogate estimate 
of lung hyperinﬂ  ation and requires no more than a simple 
spirometer for its measurement. Assessing changes in IC 
has been proposed as an important predictor of therapeutic 
response to bronchodilator therapy in COPD (Tantucci et al 
1998; O’Donnell et al 1999, 2001; Duranti et al 2002).
For the COPD group, there was no change in the mean 
IC over the admission and no correlation between change 
in IC and change in dyspnea. However it was noted that the 
COPD patients who showed the largest improvement in IC 
over the admission (410 ml increase) also showed the largest 
improvement in resting dyspnea (−2 in Borg score). It has 
been suggested that an improvement in IC of equal to or 
greater than 10% of the predicted value corresponds with a 
real improvement in exercise performance (O’Donnell et al 
1999). Four of the ten patients in the asthma group and two of 
eight COPD patients exhibited such a change in IC over the 
course of the admission. However there were no signiﬁ  cant 
differences in the changes in dyspnea scores between these 
‘responders’ and the rest of the groups. This also applies to 
those who had at least a 10% of predicted acute improve-
ment in IC in response to bronchodilator (two of ten and 
two of eight at admission, and two of ten and one of eight at 
discharge for asthma and COPD respectively).
Given that IC has been shown to provide a simple mea-
sure of hyperinﬂ  ation which correlates with symptoms of 
dyspnea and exercise intolerance, it is not unreasonable 
to expect that IC should provide a useful index to monitor 
disease state during acute exacerbations of COPD. Our data 
show that over the course of an admission for treatment of 
disease exacerbations there was a measurable improvement 
in all spirometric indices in the asthma group, but in none 
for the COPD group. This is a not unexpected result for a 
measure of ventilatory function, given the nature of the two 
diseases – at least partly reversible obstruction for asthma, 
but essentially ﬁ  xed airways disease for COPD.
Our data show that IC did not change signiﬁ  cantly over 
an average 3 day hospital admission for COPD exacerbation. 
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Figure 1 Respiratory function and dyspnea scores at admission and at discharge for 
the asthma group (•) and for the COPD group ({). Each data pair represents the pre 
and post bronchodilator value obtained for each individual patient.
Table 2b Mean (SEM) respiratory function and dyspnea data for patients with COPD.  Baseline to post bronchodilator (BD) t-test 
comparisons are indicated by the p-value in the table
 Admission      Discharge
  Baseline  Post BD  p  Baseline  Post BD  p
FEV1 (L)  1.05 (0.13)  1.16 (0.14)  0.12  1.08 (0.11)  1.13 (0.11)  0.22
VC (L)  2.58 (0.23)  2.77 (0.27)  0.06  2.63 (0.24)  2.70 (0.27)  0.49
FEV1/VC (%)  40 (2.5)  42 (2.8)  0.55  41 (2.1)  42 (2.1)  0.11
IC (L)  1.93 (0.19)  2.05 (0.24)  0.09  1.94 (0.15)  2.03 (0.17)  0.27
Dyspnea (Borg)  3.5 (0.5)  2.7 (0.4)  0.04  2.6 (0.4)  2.1 (0.3)  0.02International Journal of COPD 2007:2(4) 655
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This is a similar ﬁ  nding to that of Parker et al (2005) who 
did not ﬁ  nd any signiﬁ  cant change over 7 days of recovery 
in a group of 20 COPD patients with less severe exacerba-
tions, most of which did not require hospitalization. They 
did however ﬁ  nd signiﬁ  cant improvements in IC at 14 days 
which coincided with dyspnea improvements.
The observed improvement in resting dyspnea in the 
COPD group despite the lack of measurable physiologi-
cal change may relate to the known euphoriant effect of 
corticosteroids in this patient group. There may also have 
also been a potential ‘I am being discharged therefore I must 
be feeling better’ phenomenon, however an improvement in 
dyspnea was not observed in the asthmatic group where a 
similar effect could be expected. Dyspnea in COPD is likely 
multifactorial in origin, with hyperinﬂ  ation being only one 
of several mechanisms which may induce this symptom. 
Other factors which may impact on the cognitive sensation of 
dyspnea include the mechanical status of the chest (including 
degree of airﬂ  ow obstruction) and the degrees of integration 
of respiratory afferent activity, respiratory motor drive, affec-
tive state, attention, experience and learning which exist in 
the individual patient (O’Donnell DE et al 2007).
In our asthma group, self-perceived dyspnea on discharge 
from hospital did not improve despite the improvement in 
ventilatory function. In asthma, the perception of dyspnea 
during induced bronchoconstriction is known to be dimin-
ished in the presence of baseline airﬂ  ow obstruction (Burdon 
et al 1982). This is possibly due to a developing adaptation 
to poor lung function during periods of worsening asthma 
(Salome et al 2002). At the time of admission when our sub-
jects with asthma are clearly in a state of suboptimal asthma 
control, it is not unreasonable to expect poor perception of 
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Figure 2 Acute changes in FEV1 and IC plotted against changes in dyspnea scores in response to inhaled bronchodilator at time of admission for both the asthma group (•) 
and for the COPD group ({). Correlation coefﬁ  cients are not signiﬁ  cant for all groups.
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Figure 3 Changes in FEV1 and IC plotted against changes in dyspnea scores over the course of the admission for both the asthma group (•) and for the COPD group ({). 
Correlation coefﬁ  cients are not signiﬁ  cant for all groups.International Journal of COPD 2007:2(4) 656
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dyspnea and therefore dyspnea ratings somewhat unrelated 
to airway caliber. There is also evidence that perception of 
dyspnea improves with steroid therapy (Salome et al 2002) 
and given that systemic corticosteroid therapy provides 
the mainstay of inpatient asthma management, our asthma 
patients are probably better perceivers of bronchial status 
at discharge compared with at admission. It is therefore not 
surprising that dyspnea on discharge from hospital did not 
improve despite improvement in ventilatory function.
The utility of IC as a measure of lung hyperinﬂ  ation 
has been shown to be closely related to dyspnea during 
methacholine-induced bronchoconstriction in asthma 
(Lougheed et al 1993; Tantucci et al 1999). Its use in assess-
ing bronchodilator response has received less interest in 
asthma than in COPD, presumably because of the utility of 
monitoring FEV1 in this disease. In one study in stable, mild 
asthma there was no correlation between change in dyspnea 
with change in FRC following bronchodilator (Lavietes et al 
2001), and a similar ﬁ  nding in another study during acute 
exacerbations of asthma (Rosi et al 2002). Our data support 
these ﬁ  ndings and differ from those assessing relationships 
between dyspnea and IC during induced bronchoconstriction 
(Lougheed et al 1993; Tantucci et al 1999). The differences 
in nature of onset of bronchoconstriction could explain 
these contrasting ﬁ  ndings – acute bronchoconstriction from 
a relatively well preserved baseline is quite different from 
the slowly progressing deterioration that often precedes an 
exacerbation. Symptom perception is likely to be heightened 
in the former case whereas an adaptation or tolerance to 
impaired function may develop in the latter.
The lack of association between a change in IC and a 
change in dyspnea was not simply due to a lack of statistical 
power. Based on the data in the current study and assuming 
an α (signiﬁ  cance) of 0.05 and a β (power) of 0.8, 78 subjects 
with asthma and 51 with COPD would have had to be tested 
to ﬁ  nd a statistically signiﬁ  cant association. These large 
numbers suggest the test has little clinical utility during 
exacerbations of COPD or asthma.
In summary, we have not been able to demonstrate any 
relationship between patient-perceived dyspnea and spiro-
metric measurements of ventilatory function during acute 
exacerbations of asthma or COPD. In particular, changes 
in inspiratory capacity in these two disease states were not 
found to correlate with changes in dyspnea either as an acute 
response to bronchodilator, or in response to changes elicited 
during a hospital admission. A role for IC monitoring in the 
management of acute exacerbations of COPD and asthma 
has not been identiﬁ  ed.
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